AHA

Novel agent shortened episodes versus placebo

Significantly lower diastolic blood pressure at 12 weeks, U.S.-based study showed

Aprocitentan targets the endothelin pathway, whereas baxdrostat blocks aldosterone production

Epicardial botulinum toxin generally not better than placebo in the NOVA study

Also reduced risk of composite endpoint of death, MI, and catheterization compared with usual care

Largest-yet RCT shows no benefit for non-hospitalized symptomatic patients despite elevated risk

High-cost procedure not yet justified as an early strategy

Randomized trial shows advantages across heart failure spectrum

BRIGHT-4 trial hands the drug a "clear, unambiguous win" against heparin

Extended follow-up of ISCHEMIA trial weighs in on mortality

While findings were not significant, the study was impacted by COVID lockdowns, researcher says

LDL cholesterol reductions with cinnamon, garlic, and others not on par with statin

Pathways for HF patients picked for early discharge versus admission

STRESS trial misses primary endpoint but secondary benefits are suggestive